Abstract
The Na+/H+-exchanger 1, NHE1 (SLC9A1) and the electroneutral Na+,HCO3 --cotransporter NBCn1 (SLC4A7) are coexpressed in a wide range of tissues. Under normal physiological conditions these transporters play an ostensibly similar role, namely that of net acid extrusion after cellular acidification. In addition, they have been implicated in multiple other cellular processes, including regulation of transepithelial transport, cell volume, cell death/survival balance, and cell motility. In spite of their apparent functional similarity, the two transporters also serve distinctly different functions and are differentially regulated. Here, we provide an update on the basic structure, function, regulation, physiology and pharmacology of NHE1 and NBCn1, with particular focus on the factors responsible for their functional similarities and differences. Finally, we highlight recent findings implicating these transporters in cancer development, and discuss issues relating to NHE1 and NBCn1 as potential targets in cancer treatment.
Keywords: SLC9A1, SLC4A7, cancer, acidification, bicarbonate, EIPA, cariporide, DIDS, S0859, Na+/H+-exchanger 1
Current Pharmaceutical Design
Title: Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Volume: 18 Issue: 10
Author(s): E. Boedtkjer, L. Bunch and S. F. Pedersen
Affiliation:
Keywords: SLC9A1, SLC4A7, cancer, acidification, bicarbonate, EIPA, cariporide, DIDS, S0859, Na+/H+-exchanger 1
Abstract: The Na+/H+-exchanger 1, NHE1 (SLC9A1) and the electroneutral Na+,HCO3 --cotransporter NBCn1 (SLC4A7) are coexpressed in a wide range of tissues. Under normal physiological conditions these transporters play an ostensibly similar role, namely that of net acid extrusion after cellular acidification. In addition, they have been implicated in multiple other cellular processes, including regulation of transepithelial transport, cell volume, cell death/survival balance, and cell motility. In spite of their apparent functional similarity, the two transporters also serve distinctly different functions and are differentially regulated. Here, we provide an update on the basic structure, function, regulation, physiology and pharmacology of NHE1 and NBCn1, with particular focus on the factors responsible for their functional similarities and differences. Finally, we highlight recent findings implicating these transporters in cancer development, and discuss issues relating to NHE1 and NBCn1 as potential targets in cancer treatment.
Export Options
About this article
Cite this article as:
Boedtkjer E., Bunch L. and F. Pedersen S., Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy, Current Pharmaceutical Design 2012; 18 (10) . https://dx.doi.org/10.2174/138161212799504830
DOI https://dx.doi.org/10.2174/138161212799504830 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Patents Involving Virus Nucleotide Sequences; Host Defense, RNA Silencing and Expression Vector Strategies
Recent Patents on DNA & Gene Sequences Particle Sorting in Microfluidic Systems
Micro and Nanosystems Targeting Protein Degradation in Cancer Treatment
Current Chemical Biology Modulation of Toll-Like Receptor 4. Insights from X-Ray Crystallography and Molecular Modeling
Current Topics in Medicinal Chemistry Patent Selections
Recent Patents on Biomarkers Gene Therapy to Overcome Drug Resistance in Cancer: Targeting Key Regulators of the Apoptotic Pathway
Current Gene Therapy ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science Vaccines and Other Immunological Approaches for Cancer Immunoprevention
Current Drug Targets MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Cyclooxygenase-2: Potential Role in Regulation of Drug Efflux and Multidrug Resistance Phenotype
Current Pharmaceutical Design Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Recent Patents on Anti-Cancer Drug Discovery Effects of Highly Active Antiretroviral Therapy on HIV-1-Associated Oral Complications
Current HIV Research Pharmacological Intervention at CCR1 and CCR5 as an Approach for Cancer: Help or Hindrance
Current Topics in Medicinal Chemistry p16<sup>INK4</sup> as a Biomarker in Oropharyngeal Squamous Cell Carcinoma
Recent Patents on Biomarkers Patent Selections
Recent Patents on Anti-Cancer Drug Discovery A Link Between Chemical Structure and Biological Activity in Triterpenoids
Recent Patents on Anti-Cancer Drug Discovery Peptides in Melanoma Therapy
Current Pharmaceutical Design Identification of Novel 5,6-Dimethoxyindan-1-one Derivatives as Antiviral Agents
Medicinal Chemistry Anticancer Drugs Discovery and Development from Marine Organisms
Current Topics in Medicinal Chemistry